King's College London

Research portal

Novel systemic therapies in atopic dermatitis: what do we need to fulfil the promise of a treatment revolution?

Research output: Contribution to journalReview article

Helen Alexander, Thomas Patton, Zarif K. Jabbar-Lopez, Andrea Manca, Carsten Flohr

Original languageEnglish
Article number132
JournalF1000Research
Volume8
DOIs
Publication statusPublished - 1 Jan 2019

King's Authors

Abstract

Patients with atopic dermatitis (AD) who do not adequately respond to topical therapy and phototherapy often need systemic immunomodulatory treatment to control their symptoms. Conventional systemic agents, such as ciclosporin, azathioprine, and methotrexate, have been used for decades, but there are concerns about their safety profile. There are now many novel systemic agents emerging through clinical trials, which may have great potential in the treatment of AD. Despite this, there are very few data comparing the performance of these drugs against each other. The purpose of this article is to review the current systemic therapies in AD and present an indirect comparison of systemic AD treatments using effectiveness and safety data from published randomised controlled trials, highlighting important remaining gaps in knowledge. Although the latest developments in systemic AD treatments are exciting and dearly needed, further work is required before the promise of a therapeutic revolution becomes reality.

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454